eMind and St. Marianna University School of Medicine Conclude Comprehensive Partnership Agreement | Accelerating Next-Generation Medical Innovation in SaMD and Non-SaMD Fields with Proprietary AI Technology
eMind Inc. and St. Marianna University School of Medicine have signed a comprehensive partnership agreement. This collaboration aims to leverage eMind's unique AI technology and St. Marianna University's clinical data to accelerate innovation in next-generation digital healthcare, serving the wider society.
📋 Article Processing Timeline
- 📰 Published: April 28, 2026 at 21:00
- 🔍 Collected: April 28, 2026 at 12:31
- 🤖 AI Analyzed: April 28, 2026 at 12:47 (15 min after Collected)
eMind Inc. (Head Office: Chiyoda-ku, Tokyo; Representative: David Liebreich; hereinafter "eMind") and St. Marianna University School of Medicine (Location: Kawasaki City, Kanagawa Prefecture; President: Hiroaki Kitagawa; hereinafter "St. Marianna University School of Medicine") have concluded a "Comprehensive Partnership Agreement" with the aim of utilizing the clinical and other data held by St. Marianna University School of Medicine to widely benefit society through digital healthcare applications developed by eMind.
A signing ceremony was held on April 22, attended by Hiroaki Kitagawa, President of St. Marianna University School of Medicine; Dr. Yoshihisa Yamano, Professor and Dean of the Department of Neurology and Neuroscience; Dr. Atsuo Nakagawa, Professor of Neuropsychiatry; and David Liebreich, Representative Director and CEO of eMind.
(From left to right in the image) David Liebreich, Representative Director and CEO of eMind, Hiroaki Kitagawa, President of St. Marianna University School of Medicine.
Accelerating Medical DX and New Approaches Opened Up by eMind's AI
Currently, Japan faces structural challenges such as a shortage of medical resources and strained medical finances due to the advancement of a super-aging society. Against this backdrop, there is an urgent need to promote the sharing of medical information using digital technology and the promotion of "PHR (Personal Health Record)" where patients manage and utilize their own health data. Establishing mechanisms for early disease detection and prevention in society is one of the most important themes in Japanese medicine.
eMind has been researching and developing patented AI technology that predicts diseases by deriving digital biomarkers through passive data collection from smartphones and other devices. This approach, based on real-world data obtained from daily life, is characterized by its ability to continuously acquire data while minimizing the burden on patients, and can serve as a foundation for creating new evidence through out-of-clinic monitoring.
In this collaboration, by combining this technology with the abundant clinical data and advanced clinical knowledge possessed by St. Marianna University School of Medicine, we aim to realize disease identification and early detection for unexamined and undiagnosed populations, which have previously been difficult to approach. Furthermore, by continuously acquiring behavioral data, we will objectively grasp the mental and physical condition of patients, including during periods without medical consultations, and strongly promote the monitoring and support of disease treatment. Concurrently, we will aim for the continuous accumulation of high-quality real-world evidence (RWE) through the construction and operation of disease registries.
Towards the Realization of Next-Generation Digital Healthcare Connecting Medicine and Daily Life
Based on these initiatives, in the future, we aim to develop program medical devices (SaMD) that supplement or replace conventional drug therapies, and to resolve drug lag and drug loss through support for decentralized clinical trials (DCT) and post-marketing surveillance. The innovation targeted by this partnership extends not only to the SaMD domain but also to the wellness and prevention domains (Non-SaMD).
In addition to improving the quality of medical care, we will prioritize improving patients' QOL and pursuing their satisfaction, accelerating the social implementation of digital healthcare rooted in daily life. Furthermore, through active human exchange and educational support between industry and academia, we will focus on nurturing professional human resources who will lead the next generation of medicine.
Moving forward, eMind and St. Marianna University School of Medicine will leverage their human, tangible, and intellectual resources to the fullest extent under close cooperation and collaboration, contributing to the further development of medical care and medicine in Japan, and the realization of a society where everyone can live healthily.
Group photo of eMind and St. Marianna University School of Medicine personnel (Image left: Dr. Yoshihisa Yamano, Professor and Dean of the Department of Neurology and Neuroscience; Image right: Dr. Atsuo Nakagawa, Professor of Neuropsychiatry).
Inquiries regarding this matter
eMind Inc. Clinical Research Promotion Department
Inquiry Form: https://emind.jp/#contact
St. Marianna University School of Medicine General Affairs Department, General Affairs Division
TEL: 044-977-8111 (Extension: 3181)
E-Mail: soumu@marianna-u.ac.jp
About eMind Inc.
eMind Inc. was founded in July 2020 with the mission to "support people's mental and physical health and contribute to society." We promote DX (Digital Transformation) in the mental health and neurological disorder fields, and are engaged in the development and provision of innovative digital healthcare solutions through collaboration with medical institutions and partner companies. We possess proprietary technology (Patent No. 6841466) that predicts the severity of depression by digital biomarkers obtained from smartphones, and have been offering the employee and organizational support service "eMind for Business" utilizing this technology since October 2022. In May 2024, we jointly developed with Tohoku University...
A signing ceremony was held on April 22, attended by Hiroaki Kitagawa, President of St. Marianna University School of Medicine; Dr. Yoshihisa Yamano, Professor and Dean of the Department of Neurology and Neuroscience; Dr. Atsuo Nakagawa, Professor of Neuropsychiatry; and David Liebreich, Representative Director and CEO of eMind.
(From left to right in the image) David Liebreich, Representative Director and CEO of eMind, Hiroaki Kitagawa, President of St. Marianna University School of Medicine.
Accelerating Medical DX and New Approaches Opened Up by eMind's AI
Currently, Japan faces structural challenges such as a shortage of medical resources and strained medical finances due to the advancement of a super-aging society. Against this backdrop, there is an urgent need to promote the sharing of medical information using digital technology and the promotion of "PHR (Personal Health Record)" where patients manage and utilize their own health data. Establishing mechanisms for early disease detection and prevention in society is one of the most important themes in Japanese medicine.
eMind has been researching and developing patented AI technology that predicts diseases by deriving digital biomarkers through passive data collection from smartphones and other devices. This approach, based on real-world data obtained from daily life, is characterized by its ability to continuously acquire data while minimizing the burden on patients, and can serve as a foundation for creating new evidence through out-of-clinic monitoring.
In this collaboration, by combining this technology with the abundant clinical data and advanced clinical knowledge possessed by St. Marianna University School of Medicine, we aim to realize disease identification and early detection for unexamined and undiagnosed populations, which have previously been difficult to approach. Furthermore, by continuously acquiring behavioral data, we will objectively grasp the mental and physical condition of patients, including during periods without medical consultations, and strongly promote the monitoring and support of disease treatment. Concurrently, we will aim for the continuous accumulation of high-quality real-world evidence (RWE) through the construction and operation of disease registries.
Towards the Realization of Next-Generation Digital Healthcare Connecting Medicine and Daily Life
Based on these initiatives, in the future, we aim to develop program medical devices (SaMD) that supplement or replace conventional drug therapies, and to resolve drug lag and drug loss through support for decentralized clinical trials (DCT) and post-marketing surveillance. The innovation targeted by this partnership extends not only to the SaMD domain but also to the wellness and prevention domains (Non-SaMD).
In addition to improving the quality of medical care, we will prioritize improving patients' QOL and pursuing their satisfaction, accelerating the social implementation of digital healthcare rooted in daily life. Furthermore, through active human exchange and educational support between industry and academia, we will focus on nurturing professional human resources who will lead the next generation of medicine.
Moving forward, eMind and St. Marianna University School of Medicine will leverage their human, tangible, and intellectual resources to the fullest extent under close cooperation and collaboration, contributing to the further development of medical care and medicine in Japan, and the realization of a society where everyone can live healthily.
Group photo of eMind and St. Marianna University School of Medicine personnel (Image left: Dr. Yoshihisa Yamano, Professor and Dean of the Department of Neurology and Neuroscience; Image right: Dr. Atsuo Nakagawa, Professor of Neuropsychiatry).
Inquiries regarding this matter
eMind Inc. Clinical Research Promotion Department
Inquiry Form: https://emind.jp/#contact
St. Marianna University School of Medicine General Affairs Department, General Affairs Division
TEL: 044-977-8111 (Extension: 3181)
E-Mail: soumu@marianna-u.ac.jp
About eMind Inc.
eMind Inc. was founded in July 2020 with the mission to "support people's mental and physical health and contribute to society." We promote DX (Digital Transformation) in the mental health and neurological disorder fields, and are engaged in the development and provision of innovative digital healthcare solutions through collaboration with medical institutions and partner companies. We possess proprietary technology (Patent No. 6841466) that predicts the severity of depression by digital biomarkers obtained from smartphones, and have been offering the employee and organizational support service "eMind for Business" utilizing this technology since October 2022. In May 2024, we jointly developed with Tohoku University...